Yesafili

Yesafili (aflibercept) is a biosimilar intravitreal injection used to treat retinal conditions like wet age-related macular degeneration and diabetic macular edema. It targets abnormal blood vessel growth in the eye. This EU-manufactured treatment supports vascular eye health.

Yesafili (aflibercept) is used to treat retinal disorders caused by abnormal blood vessel growth, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It helps reduce fluid leakage and swelling in the retina, supporting clearer vision. This intravitreal injection is designed for ocular use to maintain retinal health.

After administration, Yesafili works locally in the eye to slow the progression of retinal conditions by targeting vascular endothelial growth factor (VEGF). Patients may notice improved vision clarity over time as swelling and leakage decrease. Regular monitoring with an eye care professional is recommended to assess ongoing benefits.

Yesafili is for intravitreal use only and should be handled by a healthcare professional. Patients with eye infections or inflammation should inform their provider before treatment. Temporary vision changes may occur after injection; avoid rubbing the eye or driving until cleared by a doctor. Store in a cool, dry place away from light.

Concurrent use of other intravitreal therapies or systemic VEGF inhibitors may increase the risk of ocular side effects. Patients using blood thinners or with a history of eye surgery should discuss risks with their healthcare provider. Alcohol consumption does not directly interact but may affect overall eye health.